TR201819802T4 - 18F etiketli folat/antifolat analogları. - Google Patents

18F etiketli folat/antifolat analogları. Download PDF

Info

Publication number
TR201819802T4
TR201819802T4 TR2018/19802T TR201819802T TR201819802T4 TR 201819802 T4 TR201819802 T4 TR 201819802T4 TR 2018/19802 T TR2018/19802 T TR 2018/19802T TR 201819802 T TR201819802 T TR 201819802T TR 201819802 T4 TR201819802 T4 TR 201819802T4
Authority
TR
Turkey
Prior art keywords
folate
antifolate
labeled folate
analogs
antifolate analogs
Prior art date
Application number
TR2018/19802T
Other languages
English (en)
Turkish (tr)
Inventor
Schibli Roger
Moser Rudolf
Magdalena Müller Cristina
Mensah Ametamey Simon
Betzel Thomas
Groehn Viola
Original Assignee
Merck & Cie
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Cie filed Critical Merck & Cie
Publication of TR201819802T4 publication Critical patent/TR201819802T4/tr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/002—Heterocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/06—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4
    • C07D475/08—Heterocyclic compounds containing pteridine ring systems with a nitrogen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR2018/19802T 2012-05-08 2013-05-08 18F etiketli folat/antifolat analogları. TR201819802T4 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12167126 2012-05-08

Publications (1)

Publication Number Publication Date
TR201819802T4 true TR201819802T4 (tr) 2019-01-21

Family

ID=48407549

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2018/19802T TR201819802T4 (tr) 2012-05-08 2013-05-08 18F etiketli folat/antifolat analogları.

Country Status (17)

Country Link
US (1) US10357576B2 (cg-RX-API-DMAC7.html)
EP (1) EP2864329B1 (cg-RX-API-DMAC7.html)
JP (1) JP6198814B2 (cg-RX-API-DMAC7.html)
KR (1) KR102116000B1 (cg-RX-API-DMAC7.html)
CN (1) CN104379585B (cg-RX-API-DMAC7.html)
AU (1) AU2013258027B2 (cg-RX-API-DMAC7.html)
CA (1) CA2870124C (cg-RX-API-DMAC7.html)
DK (1) DK2864329T3 (cg-RX-API-DMAC7.html)
EA (1) EA201401225A1 (cg-RX-API-DMAC7.html)
ES (1) ES2703627T3 (cg-RX-API-DMAC7.html)
IL (1) IL235476B (cg-RX-API-DMAC7.html)
PL (1) PL2864329T3 (cg-RX-API-DMAC7.html)
PT (1) PT2864329T (cg-RX-API-DMAC7.html)
SG (1) SG11201406481TA (cg-RX-API-DMAC7.html)
TR (1) TR201819802T4 (cg-RX-API-DMAC7.html)
WO (1) WO2013167653A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201407266B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101646577B1 (ko) * 2014-08-14 2016-08-09 원광대학교산학협력단 엽산수용체 표적용 화합물 또는 이의 약학적으로 허용가능한 염과, 이를 유효성분으로 포함하는 암 예방, 진단 또는 치료용 조성물
AU2018237784B2 (en) * 2017-03-20 2022-04-21 Merck Patent Gmbh Isomerically pure 18F-labelled tetrahydrofolates
EP3671511B1 (en) 2018-12-19 2022-07-06 Rohde & Schwarz GmbH & Co. KG Communication system and method
DE102019110904B4 (de) * 2019-04-26 2022-01-20 Helmholtz-Zentrum Dresden - Rossendorf E. V. N-(4-methoxy-7-morpholinobenzo[d]thiazol-2-yl)-acetamid-Derivate und deren Verwendung
WO2021257857A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Naphthyridinone compounds as jak2 v617f inhibitors
WO2021257863A1 (en) 2020-06-19 2021-12-23 Incyte Corporation Pyrrolotriazine compounds as jak2 v617f inhibitors
IL299612A (en) 2020-07-02 2023-03-01 Incyte Corp Tricyclic urea compounds as JAK2 V617F inhibitors
US11767323B2 (en) 2020-07-02 2023-09-26 Incyte Corporation Tricyclic pyridone compounds as JAK2 V617F inhibitors
US11661422B2 (en) 2020-08-27 2023-05-30 Incyte Corporation Tricyclic urea compounds as JAK2 V617F inhibitors
US11919908B2 (en) 2020-12-21 2024-03-05 Incyte Corporation Substituted pyrrolo[2,3-d]pyrimidine compounds as JAK2 V617F inhibitors
CA3211748A1 (en) 2021-02-25 2022-09-01 Incyte Corporation Spirocyclic lactams as jak2 v617f inhibitors
IL315647A (en) 2022-03-17 2024-11-01 Incyte Corp Tricyclic urea compounds as Jak2 and 617f inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2592302C (en) 2004-12-23 2013-10-29 Purdue Research Foundation Positron emission tomography imaging method
JP4503039B2 (ja) 2006-04-27 2010-07-14 三洋電機株式会社 回路装置
US8586595B2 (en) 2007-02-07 2013-11-19 Purdue Research Foundation Positron emission tomography imaging method
US20100143249A1 (en) 2007-04-11 2010-06-10 Merck Eprova Ag Folate-conjugates and corresponding metal-chelate complexes for use in diagnostic imaging and radiotherapy
CN101646639A (zh) 2007-04-11 2010-02-10 默克阿泼洛发股份公司 18f-标记的叶酸
TR201901010T4 (tr) * 2007-04-11 2019-02-21 Merck & Cie 18F etiketli folatlar.
WO2008125615A1 (en) 2007-04-11 2008-10-23 Merck Eprova Ag 18 f-labelled folates
CA2736861C (en) 2008-10-10 2017-11-14 Roger Schibli 18f-labelled folates as pet radiotracers

Also Published As

Publication number Publication date
WO2013167653A1 (en) 2013-11-14
ES2703627T3 (es) 2019-03-11
IL235476A0 (en) 2014-12-31
US20150125390A1 (en) 2015-05-07
CN104379585A (zh) 2015-02-25
AU2013258027A1 (en) 2014-11-13
AU2013258027B2 (en) 2017-11-30
KR20150010970A (ko) 2015-01-29
JP2015516405A (ja) 2015-06-11
CN104379585B (zh) 2018-07-06
PL2864329T3 (pl) 2019-03-29
ZA201407266B (en) 2016-09-28
CA2870124A1 (en) 2013-11-14
SG11201406481TA (en) 2014-11-27
CA2870124C (en) 2021-02-16
DK2864329T3 (en) 2019-01-21
EP2864329B1 (en) 2018-09-26
KR102116000B1 (ko) 2020-05-29
PT2864329T (pt) 2019-01-10
JP6198814B2 (ja) 2017-09-20
US10357576B2 (en) 2019-07-23
IL235476B (en) 2019-09-26
HK1202548A1 (en) 2015-10-02
EA201401225A1 (ru) 2015-04-30
EP2864329A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
EA201401225A1 (ru) F-меченые аналоги фолата/антифолата
CY1125092T1 (el) Ιατρικη χρηση σχετικα με επεκταση τελομερους
CY1123106T1 (el) Αγωγη ανοσοσχετιζομενων και φλεγμονωδων νοσων
MX358517B (es) Métodos para determinar eficacia de fármacos usando proteínas asociadas a cereblon.
MX353482B (es) Metodos para el tratamiento del cancer y enfermedades inflamatorias utilizando cereblon como predictor.
EA201890013A1 (ru) Способы получения tcr гамма дельтат-клеток
CR20150370A (es) Compuestos antivirales
MA34091B1 (fr) Anticorps anti-cd40
GT201500093A (es) Moduladores de quinolinilo unidos a metileno de ror- gamma-t
EP2852671A4 (en) GENERATION OF HUMAN IPS CELLS BY SYNTHETIC SELF-REPLICATIVE RNA
CL2014003110A1 (es) Anticuerpo anti-fcrn; secuencias que lo codifican; vector; célula huésped; proceso de producción; composición farmacéutica que lo comprende; uso para el tratamiento de enfermedad autoinmune; y ensayo para probar la capacidad de un anticuerpo para bloquear la actividad de fcrn humano.
UY35177A (es) Novedosos derivados de bencimidazol como antagonistas de ep4
EA201491973A1 (ru) Новые соединения
EA201391187A1 (ru) Способ диагностики злокачественной опухоли и набор для диагностики путем измерения активности nk-клеток
UY34467A (es) Procedimiento para la preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
JO3154B1 (ar) عوامل مضادة لـ trpv4
NI201500050A (es) Benzamidas
MX359769B (es) Metodos para descelularizar huesos.
DOP2014000199A (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
EA201400623A1 (ru) Новые 2h-индазолы в качестве антагонистов рецептора ep
EA201591742A1 (ru) Способ улучшения диагностики заболеваний с использованием измеряемых аналитов
EA200901347A1 (ru) F-меченые фолаты
EP2814947A4 (en) PHENOTYPE PROFILE OF HUMAN RETINA TEMPLATE CELLS
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
CY1116720T1 (el) Παραγωγα 2-αμινο-3-(ιμιδαζολ-2-υλ)-πυριδιν-4-ονης και η χρηση τους ως αναστολεις κινασης υποδοχεα vegf